{
    "Case ID": "020158",
    "Different Crime": [
        {
            "Crime Name": "Patent Infringement Dispute",
            "Crime Type": "Economic_Crimes_or_Fraud-related_Offenses",
            "legal_basis": [
                "Patented Medicines (Notice of Compliance) Regulations"
            ],
            "evidence_provided": [
                "no evidence provided by AstraZeneca showing amorphous tablets could result from crystalline material or fraud"
            ],
            "applicable_statute": [
                "Patented Medicines (Notice of Compliance) Regulations"
            ],
            "party_involved": [
                "Apotex",
                "AstraZeneca"
            ],
            "claim_nature": [
                "non-infringement of patent"
            ],
            "judicial_authority": [
                "Federal Court"
            ],
            "patent_validity": [
                "'794 Patent regarding magnesium omeprazole formulation"
            ],
            "technical_details": [
                "amorphous magnesium omeprazole",
                "crystallinity of raw materials"
            ],
            "decision_outcome": [
                "NOA deemed sufficient",
                "application dismissed"
            ],
            "cause_of_action": [
                "Dispute over alleged non-infringement"
            ],
            "nature_of_offense": [
                "Patent infringement allegation"
            ],
            "appeal_outcome": [
                "Not applicable"
            ]
        }
    ]
}